Aquestive Therapeutics, Inc. Total Revenue

• Aquestive Therapeutics, Inc. showed a decrease of -22.6% in Total Revenue from 2024 to 2025.
• This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
• XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $16.44 million | Q2 2017: $11.14 million | Q3 2017: $27.15 million | Q4 2017: $12.19 million | Q1 2018: $23.41 million | Q1 2018: $23.41 million | Q2 2018: $13.93 million | Q2 2018: $13.93 million | Q3 2018: $13.27 million | Q3 2018: $13.27 million | Q4 2018: $16.82 million | Q4 2018: $16.82 million | Q1 2019: $12.64 million | Q2 2019: $11.13 million | Q3 2019: $12.42 million | Q4 2019: $16.42 million | Q1 2020: $8.77 million | Q2 2020: $21.68 million | Q3 2020: $8.26 million | Q4 2020: $7.15 million | Q1 2021: $11.12 million | Q2 2021: $15.35 million | Q3 2021: $13.29 million | Q1 2022: $12.27 million | Q2 2022: $13.27 million | Q3 2022: $11.46 million | Q1 2023: $11.13 million | Q2 2023: $13.24 million | Q3 2023: $13.00 million | Q1 2024: $12.05 million | Q2 2024: $20.10 million | Q3 2024: $13.54 million | Q1 2025: $8.72 million | Q2 2025: $10.00 million | Q3 2025: $12.81 million.
• Over the full 10 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Total Revenue has declined by 33.4%.
• Historical annual values: Fiscal year 2025: $44.55 million | Fiscal year 2024: $57.56 million | Fiscal year 2023: $50.58 million | Fiscal year 2022: $47.68 million | Fiscal year 2021: $50.83 million | Fiscal year 2020: $45.85 million | Fiscal year 2019: $52.61 million | Fiscal year 2018: $67.43 million | Fiscal year 2018: $67.43 million | Fiscal year 2017: $66.92 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026